ArticleScientific reports2025
Engineered biodegradable polymeric nanoparticles injectable system of atorvastatin for improved therapeutic activity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Carrier-mediated drug delivery is one of the potential approaches employed to increase drug solubility and bioavailability. Atorvastatin (ATR), a HMG CoA reductase inhibitor, is a first-line medication prescribed for the treatment of hyperlipidemia and related cardiovascular diseases. The efficacy of ATR is highly limited due to its poor solubility and low oral bioavailability. In the present study, an injectable system of ATR-loaded polymeric nanoparticles was synthesized through the spray drying technique using chitosan polymer extracted in-house from a novel source of Portunus Sanguinolentus species shells. The effect of spray dryer nozzle diameter and polymer concentration on particle size, morphology, in vitro drug release, and ex vivo permeation was studied. The synthesized ATR-loaded chitosan particles were in the size range of 248.2 ± 17.58 nm to 329 ± 36.68 nm with homogeneous distribution. The average drug loading of all formulations was above 80%. The nozzle of 0.7 mm diameter produced smaller-sized particles with higher drug loading compared to the 1 mm diameter nozzle. Morphological analysis of the synthesized nanoparticles was performed using SEM, which revealed that particle size was increased linearly with increasing concentration of chitosan, with more flower-like structure deposition of polymer on the surface. The in vitro drug release and solubility study of the formulations on different bio-relevant media confirmed that the solubility of the drug was increased on all three different media as the concentration of chitosan increased. Also, the presence of chitosan improved the permeability of the drug through the membrane's adhesive property. Characterization of selected formulation with analytical techniques like FT-IR, XRD, TG-DSC confirmed that the drug was functionally active in the polymeric systems without significant alterations. Therefore, the synthesized formulation was proven to be effective in improving in vitro dissolution without significant loss, which could improve the in vivo bioavailability of Atorvastatin by enhancing solubility, absorption, and permeation in the physiological system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.